ICIG Ventures

ICIG Ventures is the corporate venture capital platform of International Chemical Investors Group (ICIG), a privately held industrial holding company. ICIG acquires and operates mid-sized chemical and pharmaceutical manufacturing sites across Europe and the United States. The venture arm invests in early-stage companies whose technologies can eventually be scaled using ICIG's own production infrastructure. This parent-subsidiary relationship provides portfolio companies with a captive path to pilot manufacturing, which traditional financial venture investors cannot offer.

International Chemical Investors Group was founded by Dr. Achim Riemann, a German chemist and entrepreneur who has led the organization since its inception. The venture arm's investment decisions are made by a committee drawn from ICIG's senior executive team, providing direct access to chemical-engineering and pharmaceutical-manufacturing expertise during technical due diligence. The firm does not publicly name a separate venture-head title distinct from the parent group's leadership.

ICIG Ventures sources opportunities through the parent group's extensive network of chemical and pharmaceutical manufacturing relationships across Europe and North America. The firm benefits from deal flow generated by ICIG's ongoing corporate development activity, including contact with universities, research institutes, and other corporate venture arms in the specialty-chemicals ecosystem. Its technical due-diligence capability, underwritten by ICIG's in-house engineering team, further attracts founders seeking industry-insider investors.

ICIG Ventures focuses on early-stage and seed investments, with a mandate covering venture capital generally within chemistry, biotechnology, and sustainable materials. The firm does not disclose a standardized check size range. Its co-investment posture is collaborative — it invests alongside traditional venture capital funds and other corporate venture arms, often providing not only capital but also a route to first industrial-scale production runs through ICIG's manufacturing sites.

There is no public exclusion list. However, the firm's mandate is tightly focused on chemistry-driven innovation — including biotechnology, pharmaceutical intermediates, specialty chemicals, and advanced materials. It is unlikely to participate in purely software-based or consumer-internet deals, given the parent group's core competency in industrial manufacturing and process engineering. Any investment outside physical-science domains would represent a notable departure from the strategic logic that created the venture arm.

ICIG Ventures inherits the centralized, founder-led governance model of its parent, International Chemical Investors Group. Dr. Achim Riemann remains the central figure; investment and strategic decisions flow through the parent group's executive layer rather than a standalone partnership. The firm has not disclosed a formal succession plan for either the industrial group or its venture activities. The governance structure resembles that of other European family- and founder-controlled industrial holding companies.

ICIG Ventures operates as a corporate venture capital vehicle fully funded by its parent group, International Chemical Investors Group. Public information does not indicate that it raises third-party capital or offers co-investment rights to external institutional limited partners. The structure is consistent with strategic corporate venture arms designed to identify technologies and teams that complement the parent's industrial operations, rather than to generate fund-management fees.